Editas Medicine (NASDAQ:EDIT)

CAPS Rating: 4 out of 5

EDIT News and Commentary

Caps

How do you think EDIT will perform against the market?

Add Stock to CAPS Watchlist

All Players

193 Outperform
7 Underperform
 

All-Star Players

90 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top EDIT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFRendezvous (89.95)
Submitted December 17, 2017

The genetic medicine field is unquestionably the future. There are a handful of "CRISPR gene editing" public biotechs, which I conveniently found on StockTwits. Was interested in it when RB made it a rec as it fits into one of my favorite long term… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

EDIT VS S&P 500 (SPY)

EDIT Summary

Fools bullish on EDIT are also bullish on:

Fools bearish on EDIT are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about EDIT.

Recs

0
Member Avatar TrevorCarson (59.86) Submitted: 6/2/2018 3:26:52 PM : Outperform Start Price: $37.10 EDIT Score: +5.82

Paladin pick

Recs

0
Member Avatar Inhouseanalyst (25.15) Submitted: 5/31/2018 12:35:27 PM : Outperform Start Price: $36.86 EDIT Score: +6.11

Gene editing will gain market with increasingly aging population.

Recs

0
Member Avatar btechrisk11 (< 20) Submitted: 4/15/2018 3:31:17 PM : Underperform Start Price: $34.93 EDIT Score: -9.58

Still a lot to learn for CRISPR technology to translate to clinic safely. CRISPR can be fairly selective but there was a recent journal article suggesting many people have antibodies/immune responses against some of the CRISPR elements.

Leaderboard

Find the members with the highest scoring picks in EDIT.

Score Leader

portefeuille

portefeuille (98.93) Score: +149.31

The Score Leader is the player with the highest score across all their picks in EDIT.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
portefeuille 98.93 2/10/2016 Outperform 5Y $13.26 +197.06% +47.74% +149.31 0 Comment
WoollyWombat < 20 9/16/2016 Outperform 5Y $14.48 +172.03% +29.12% +142.91 0 Comment
freemarketmike < 20 6/7/2017 Outperform 5Y $15.43 +155.23% +13.12% +142.11 1 Comment
FunesDMemorious 96.93 10/26/2016 Outperform 5Y $14.55 +170.72% +29.22% +141.51 0 Comment
portefeuille2 99.66 9/22/2016 Outperform 5Y $14.87 +164.90% +26.98% +137.92 0 Comment
CMFMLove 52.32 6/13/2017 Outperform 5Y $16.00 +146.19% +12.92% +133.27 1 Comment
Playa14 < 20 6/9/2017 Outperform 5Y $16.08 +144.96% +12.87% +132.09 0 Comment
forcel0 95.10 11/23/2016 Outperform 5Y $15.60 +152.50% +25.20% +127.30 0 Comment
hayrettin 70.94 7/28/2017 Outperform 5Y $16.96 +132.25% +11.69% +120.56 0 Comment
allforone 27.98 12/28/2016 Outperform 3Y $17.00 +131.70% +22.81% +108.89 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for EDIT.

Featured Broker Partners


Advertisement